MX2016001302A - Compuesto y metodos para tratar el sindrome de qt largo. - Google Patents
Compuesto y metodos para tratar el sindrome de qt largo.Info
- Publication number
- MX2016001302A MX2016001302A MX2016001302A MX2016001302A MX2016001302A MX 2016001302 A MX2016001302 A MX 2016001302A MX 2016001302 A MX2016001302 A MX 2016001302A MX 2016001302 A MX2016001302 A MX 2016001302A MX 2016001302 A MX2016001302 A MX 2016001302A
- Authority
- MX
- Mexico
- Prior art keywords
- syndrome
- compound
- methods
- treating long
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
Abstract
Se describe en la presente un método para tratar el síndrome de QT largo por la administración de una cantidad eficaz de un bloqueador de canales iónicos de sodio tardíos potente y selectivo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361861344P | 2013-08-01 | 2013-08-01 | |
| US201361900235P | 2013-11-05 | 2013-11-05 | |
| PCT/US2014/049155 WO2015017661A1 (en) | 2013-08-01 | 2014-07-31 | Compound and methods for treating long qt syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016001302A true MX2016001302A (es) | 2016-04-07 |
Family
ID=51352867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001302A MX2016001302A (es) | 2013-08-01 | 2014-07-31 | Compuesto y metodos para tratar el sindrome de qt largo. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9126989B2 (es) |
| EP (1) | EP3027190A1 (es) |
| JP (1) | JP2016525580A (es) |
| KR (1) | KR20160035061A (es) |
| CN (1) | CN105611931A (es) |
| AU (1) | AU2014296145A1 (es) |
| CA (1) | CA2919757A1 (es) |
| EA (1) | EA201690215A1 (es) |
| HK (1) | HK1219893A1 (es) |
| MX (1) | MX2016001302A (es) |
| SG (1) | SG11201600119PA (es) |
| WO (1) | WO2015017661A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
| US10575744B2 (en) | 2017-02-24 | 2020-03-03 | Medtronic Cryocath Lp | Pericardial balloon mapping |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030220344A1 (en) | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| WO2013112932A1 (en) * | 2012-01-27 | 2013-08-01 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
-
2014
- 2014-07-31 SG SG11201600119PA patent/SG11201600119PA/en unknown
- 2014-07-31 MX MX2016001302A patent/MX2016001302A/es unknown
- 2014-07-31 WO PCT/US2014/049155 patent/WO2015017661A1/en active Application Filing
- 2014-07-31 US US14/448,307 patent/US9126989B2/en active Active
- 2014-07-31 JP JP2016531900A patent/JP2016525580A/ja active Pending
- 2014-07-31 KR KR1020167005011A patent/KR20160035061A/ko not_active Application Discontinuation
- 2014-07-31 CN CN201480042409.8A patent/CN105611931A/zh active Pending
- 2014-07-31 EP EP14750949.1A patent/EP3027190A1/en not_active Withdrawn
- 2014-07-31 EA EA201690215A patent/EA201690215A1/ru unknown
- 2014-07-31 CA CA2919757A patent/CA2919757A1/en active Pending
- 2014-07-31 AU AU2014296145A patent/AU2014296145A1/en not_active Abandoned
-
2016
- 2016-07-08 HK HK16108003.0A patent/HK1219893A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3027190A1 (en) | 2016-06-08 |
| HK1219893A1 (zh) | 2017-04-21 |
| US9126989B2 (en) | 2015-09-08 |
| CA2919757A1 (en) | 2015-02-05 |
| EA201690215A1 (ru) | 2016-07-29 |
| JP2016525580A (ja) | 2016-08-25 |
| WO2015017661A1 (en) | 2015-02-05 |
| AU2014296145A1 (en) | 2016-01-28 |
| SG11201600119PA (en) | 2016-02-26 |
| KR20160035061A (ko) | 2016-03-30 |
| CN105611931A (zh) | 2016-05-25 |
| US20150038489A1 (en) | 2015-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1218854A1 (zh) | 抑制劑治療嗜酸性食管炎的方法 | |
| PT3515465T (pt) | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r | |
| MX2016002826A (es) | Anticuerpos anti-b7-h1 para tratar tumores. | |
| MY196418A (en) | Therapeutically Active Compounds and Their Methods of use | |
| PL3069375T3 (pl) | Koncentryczne źródło jonów, jonowód i sposób stosowania w jonizacji powierzchniowej APCI | |
| BR112015020159A2 (pt) | cartucho, método de fabricação de pelo menos parte do envelope de um cartucho, máquina de preparação de bebidas e sistema de preparação de bebidas | |
| SG11202009371WA (en) | Methods for treating atopic dermatitis by administering an il-4r inhibitor | |
| EP3084835A4 (en) | Techniques for improving gate control over transistor channel by increasing effective gate length | |
| PH12015501588B1 (en) | Compounds and methods for treating bacterial infections | |
| MX2016001302A (es) | Compuesto y metodos para tratar el sindrome de qt largo. | |
| MX2019012659A (es) | Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido. | |
| EA201690446A1 (ru) | Лечение множественной миеломы | |
| GB2523222B (en) | Method of correlating precursor and fragment ions | |
| MX2016002307A (es) | Tratamiento para el cancer. | |
| EP3009843A4 (en) | Method for determining dosage of erythropoiesis-stimulating agent | |
| HK1221151A1 (zh) | 用於治療鼓膜造孔插管放置後的耳部感染的方法 | |
| IN2014DN09990A (es) | ||
| MX360458B (es) | Método para ajustar dinámicamente la temporización de transmisión de paquetes. | |
| NZ715554A (en) | Method of treating hypertrophic cardiomyopathy | |
| IL243443A0 (en) | A method for reducing strontium concentration | |
| UA87944U (ru) | Способ лечения хронической тофусной подагры | |
| IN2013MU01966A (es) | ||
| IN2013CH03945A (es) | ||
| NZ743656A (en) | Methods of treating a tauopathy | |
| PT3010539T (pt) | Métodos para tratamento da polipose nasal por administração de um antagonista il-4r |